$64.99 support anchors Bio-Techne stock near current levels

Traders Union
All News
Financial News
Bio-Techne slips 0.15% as Merck deal looms

Highlights

Merck KGaA will acquire Bio-Techne Corp. in an $11.3 billion cash deal, valuing shares at $73 each.
The acquisition, one of Minnesota's largest, will be funded through a mix of cash and new debt, shifting investor focus to deal completion risk and timing.
Technical signals on TECH/USD indicate high bullish probability with an expected range of $63.99 to $77.79, though some oscillators show mixed momentum.

Merger valuation caps upside as investors focus on deal execution

Merck KGaA has entered into a definitive agreement to acquire Bio-Techne Corp. for $11.3 billion in cash, with the deal valuing Bio-Techne shares at $73 each, according to Timeswv. This board-approved transaction establishes a clear upper boundary on share value and has shifted investor attention toward the certainty and timing of the proposed merger. As Bioxconomy reported, Merck intends to fund the acquisition through a mix of cash and new debt, and the deal marks one of Minnesota's largest-ever, prompting realignment among event-driven investors as the market prices in completion risk and liquidity expectations.

Buy-side momentum confirmed as oscillators signal mixed conviction

On the technical side, the price closed above the MA-20 and MA-50 on the H1 chart and remains above the MA-200, confirming alignment across multiple timeframes. The Ichimoku Kijun at $64.99 acts as a key immediate support level. The Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both signal strong buy-side momentum, while the Relative Strength Index (RSI) reads 82.87 and the Bull/Bear Power indicator highlights intraday buyer dominance. However, oscillators are mixed, with Stochastic RSI oversold, Commodity Channel Index (CCI) neutral, and Awesome Oscillator neutral, suggesting that while directional momentum is apparent, further confirmation across indicators is limited.

Consolidation expected as breakout odds favor bullish scenario

In the near term, TECH is expected to consolidate within a typical volatility band between $63.99 and $77.79. The probability of an upward breakout remains elevated at 75%, with a baseline scenario favoring continued trade inside this corridor. A decisive move above resistance could drive the price toward the upper end of the range, while a break below the $64.99 support would open the door to a corrective pullback.

Anton Kharitonov, expert at Traders Union, sees Bio-Techne shares anchored by the Merck acquisition bid, which removes most price discovery and focuses attention on deal closure risk. He notes that while technical momentum remains strong, the stock now trades as a classic merger arbitrage candidate within a capped range. Kharitonov remains cautious given limited upside and event-driven volatility. He states, "As long as the price remains near $73, I see little opportunity — until deal certainty improves or new risks emerge, this is a wait-and-see situation."

Earlier, analysts noted that Bio-Techne was experiencing ongoing downside pressure and highlighted a prevailing environment of caution for the stock. With the Merck acquisition now establishing a clear upper limit for share value and strong momentum signals supporting price stability, investors should closely monitor any shifts in deal progress or regulatory developments as the key catalyst for future price movement.

Source of Data: TECH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.